The Lille University Hospital developped a research objective common to all the services which took care of patients, "suspected patient", "possible case", "probable case" or "confirmed case" infected with SARS-CoV-2 by constituting a prospective and a retrospective observational cohort which allowed pooling and sharing the resources and data collected. In the next two years the prospective cohort will allow to continue inclusions in a standardized way mainly for the constitution of a negative control group (excluded cases), to collect biological samples which had not been collected in the retrospective cohort so that the pathophysiology of the COVID-19 will be better apprehended as for example the inflammatory response to the viral infection. Finally in case of a second epidemic wave in the Hauts De France, it seems essential to have a defined research protocol which had already received all the necessary authorizations to guarantee cutting-edge (or quality ) research in a center like the Lille University Hospital.The aim objective of this study is to identify predictive factors of mortality to day 28 infection to SARS-CoV-2 for patients under medical care for the COVID-19 in the Lille University Hospital thanks to the constitution of an epidemiological, clinical, biological, immunological, genetic, microbiological, anatomopathologic, radiological, therapeutic database and so record the results of functional exploration exams.
This is a retrospective and prospective observational monocentric cohort study designed to
identify predictors of mortality on day 28 in patients treated at the Lille University
Hospital for COVID-19.
Inclusion Criteria:
- All adult "suspect patient", "possible case", "probable case" or "confirmed case" of
an SARS-CoV-2 infection admitted to Lille University Hospital.
Exclusion Criteria:
- Minor patient Patient under guardianship or curatorship Refusal to participate in the
study Patient for whom the collection of genetic non-opposition or consent is
impossible because of a language barrier with the patient himself or herself or with
his or her trusted person or close family.
Patient for whom the collection of genetic non-opposition or consent is impossible because
of his or her state of health at the time of inclusion in the study and for whom the
trusted person or close family member opposes participation in the study.
Translated with www.DeepL.com/Translator (free version)
Hop Claude Huriez Chr Lille
Lille, France
Investigator:
Contact: 0320445962
Marie-Charlotte CHOPIN, MD
0320445743 - +33
mariecharlotte.chopin@chru-lille.fr
Marie-Charlotte CHOPIN, MD, Principal Investigator
University Hospital, Lille